
## Joshua M Sharfstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7198672/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A cross-sectional analysis of trends in dermatology practice size in the United States from 2012 to 2020. Archives of Dermatological Research, 2023, 315, 223-229.	1.1	4
2	Sharing the Media Spotlight—Communicating About Medical Products in Development During the Pandemic. JAMA Health Forum, 2022, 3, e215246.	1.0	0
3	The Patchwork U.S. Public Health System. New England Journal of Medicine, 2022, 386, 1-4.	13.9	15
4	Assessment of Public Opinion on Transparency at the US Food and Drug Administration. JAMA Network Open, 2022, 5, e220026.	2.8	1
5	Long-Acting Cabotegravir for HIV Prevention. JAMA - Journal of the American Medical Association, 2022, 327, 921.	3.8	16
6	Incentives for COVID-19 vaccination. The Lancet Regional Health Americas, 2022, 8, 100205.	1.5	17
7	US Suicide Rates and Impact of Major Disasters Over the Last Century. primary care companion for CNS disorders, The, 2022, 24, .	0.2	3
8	Global Compassionate Use—A New Lens on a Long-standing Inequity. JAMA Health Forum, 2022, 3, e220500.	1.0	0
9	Battling Falsehoods in the COVID-19 Pandemic. JAMA Health Forum, 2022, 3, e221587.	1.0	11
10	Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA. Lancet, The, 2022, 400, 535-538.	6.3	27
11	The COVID-19 Pandemic: An Opportunity to Transform Higher Education in Public Health. Public Health Reports, 2021, 136, 23-26.	1.3	8
12	"This Level of Death, It's Newâ€â€"Health Care Workers in Their Own Words. JAMA - Journal of the American Medical Association, 2021, 325, 331.	3.8	3
13	The US Regulatory System and COVID-19 Vaccines. JAMA - Journal of the American Medical Association, 2021, 325, 1153.	3.8	5
14	Rethinking Payment and Incentives for a Healthy Early Childhood. Academic Pediatrics, 2021, 21, 225-227.	1.0	1
15	Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet, The, 2021, 397, 1165-1167.	6.3	25
16	The Pandemic and the Supply Chain: Gaps in Pharmaceutical Production and Distribution. American Journal of Public Health, 2021, 111, 635-639.	1.5	34
17	What the American Rescue Plan Means for Health Equity. JAMA Health Forum, 2021, 2, e210658.	1.0	6
18	Enhancing Community Engagement by Schools and Programs of Public Health in the United States. Annual Review of Public Health, 2021, 42, 405-421.	7.6	18

#	Article	IF	CITATIONS
19	Extreme Risk Protection Orders—A Tool for Clinicians to Prevent Gun Violence. JAMA Health Forum, 2021, 2, e210948.	1.0	2
20	Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine. JAMA - Journal of the American Medical Association, 2021, 325, 2445.	3.8	20
21	Identifying and Tracking SARS-CoV-2 Variants — A Challenge and an Opportunity. New England Journal of Medicine, 2021, 385, 389-391.	13.9	14
22	Child Health Policy and the COVID-19 Pandemic. JAMA Health Forum, 2021, 2, e212921.	1.0	2
23	Uncoupling vaccination from politics: a call to action. Lancet, The, 2021, 398, 1211-1212.	6.3	53
24	US Healthcare Policy and Child Poverty. Academic Pediatrics, 2021, 21, S88-S89.	1.0	2
25	Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet, The, 2021, 398, 2186-2192.	6.3	106
26	Product Approval and Public Health at the US Food and Drug Administration. JAMA - Journal of the American Medical Association, 2021, 326, 2469.	3.8	2
27	Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration. JAMA Internal Medicine, 2020, 180, 301.	2.6	25
28	Help Is on the Way: Medicare Coverage of Opioid Treatment Programs. Journal of the American Geriatrics Society, 2020, 68, 637-640.	1.3	6
29	Facilitating Methadone Use in Hospitals and Skilled Nursing Facilities. JAMA Internal Medicine, 2020, 180, 7.	2.6	24
30	Performance and Priorities: A Cross-sectional Study of Local Health Department Approaches to Essential Public Health Services. Public Health Reports, 2020, 135, 97-106.	1.3	5
31	Attacks on Public Health Officials During COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 741.	3.8	58
32	Resilience in Health Care Financing. JAMA - Journal of the American Medical Association, 2020, 324, 126.	3.8	3
33	The Role of Evidence in the US Response to the Opioid Crisis. Epidemiologic Reviews, 2020, 42, 167-170.	1.3	2
34	Critical Drugs for Critical Care: Protecting the US Pharmaceutical Supply in a Time of Crisis. American Journal of Public Health, 2020, 110, 1346-1347.	1.5	3
35	Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine. JAMA - Journal of the American Medical Association, 2020, 324, 1296.	3.8	21
36	Public Opinion on the Sale of Crib Bumpers. JAMA Network Open, 2020, 3, e208089.	2.8	0

#	Article	IF	CITATIONS
37	The Urgency and Challenge of Opening K-12 Schools in the Fall of 2020. JAMA - Journal of the American Medical Association, 2020, 324, 133.	3.8	61
38	How Not to Spend an Opioid Settlement. JAMA - Journal of the American Medical Association, 2020, 323, 1031.	3.8	4
39	Additional Barriers to Methadone Use in Hospitals and Skilled Nursing Facilities—Reply. JAMA Internal Medicine, 2020, 180, 615.	2.6	2
40	Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program—Reply. JAMA Internal Medicine, 2020, 180, 916.	2.6	0
41	Diagnostic Testing for the Novel Coronavirus. JAMA - Journal of the American Medical Association, 2020, 323, 1437.	3.8	209
42	Reform at the FDA—In Need of Reform. JAMA - Journal of the American Medical Association, 2020, 323, 123.	3.8	5
43	Affording Genetic Therapies in the Medicaid Program. JAMA Pediatrics, 2020, 174, 523.	3.3	3
44	A Bold Response to the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2020, 323, 1790-1791.	3.8	80
45	Analysis of Ingredients of Supplements in the National Institutes of Health Supplement Database Marketed as Containing a Novel Alternative to Anabolic Steroids. JAMA Network Open, 2020, 3, e202818.	2.8	19
46	Unexpected Health Insurance Profits and the COVID-19 Crisis. JAMA - Journal of the American Medical Association, 2020, 324, 1713.	3.8	11
47	Unexpected Health Insurance Profits and the COVID-19 Crisis. JAMA Health Forum, 2020, 1, e201094.	1.0	2
48	How the FDA should protect its integrity from politics. Nature, 2020, 585, 161-161.	13.7	7
49	Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers Within the Treatment System. NAM Perspectives, 2020, 2020, .	1.3	90
50	Resilience in Health Care Financing. JAMA Health Forum, 2020, 1, e200614.	1.0	0
51	"This Level of Death, It's Newâ€â€"Health Care Workers in Their Own Words. JAMA Health Forum, 2020, 1 e201551.	'1.0	0
52	How Not to Spend an Opioid Settlement. JAMA Health Forum, 2020, 1, e200025.	1.0	0
53	Lessons Learned From the Opioid Epidemic. JAMA - Journal of the American Medical Association, 2019, 322, 809.	3.8	16
54	Private Equity and Dermatology—First, Do No Harm. JAMA Dermatology, 2019, 155, 1007.	2.0	18

#	Article	IF	CITATIONS
55	Adolescence: An Opportunity for Population Health. Milbank Quarterly, 2019, 97, 926-929.	2.1	0
56	Introduction: State Innovation Models. Milbank Quarterly, 2019, 97, 505-505.	2.1	0
57	The Opportunity of CBD $\hat{a} \in$ "Reforming the Law. New England Journal of Medicine, 2019, 381, 297-299.	13.9	15
58	Making Amends for the Opioid Epidemic. JAMA - Journal of the American Medical Association, 2019, 321, 1446.	3.8	21
59	The Promise—and Politics—of State Innovation for Health. Milbank Quarterly, 2019, 97, 387-390.	2.1	0
60	Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. JAMA - Journal of the American Medical Association, 2019, 321, 676.	3.8	30
61	Evaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASE. Pharmacology Research and Perspectives, 2019, 7, e00552.	1.1	6
62	Comparison of US County-Level Public Health Performance Rankings With County Cluster and National Rankings. JAMA Network Open, 2019, 2, e186816.	2.8	14
63	The cost of the opioid epidemic, in context. American Journal of Managed Care, 2019, 25, S241-S242.	0.8	2
64	Commentary on â€~Revisiting the â€~paradigm shift' in opioid use: Developments and implications 10 years later'. Drug and Alcohol Review, 2018, 37, S206-S207.	1.1	2
65	A New Year's Wish on Opioids. JAMA - Journal of the American Medical Association, 2018, 319, 537.	3.8	6
66	Innovation and Entrepreneurship: Harnessing the Public Health Skill Set in a New Era of Health Reforms and Investment. Journal of Public Health Management and Practice, 2018, 24, 99-101.	0.7	12
67	Maryland's All-Payer Health Reform—A Promising Work in Progress. JAMA Internal Medicine, 2018, 178, 269.	2.6	9
68	A Health Policy Sonnet. Milbank Quarterly, 2018, 96, 9-12.	2.1	0
69	Maryland's Hospital Global Budget Program—Reply. JAMA - Journal of the American Medical Association, 2018, 320, 2040.	3.8	1
70	Public Health Rising to the Challenge: The Bloomberg American Health Initiative. Public Health Reports, 2018, 133, 3S-4S.	1.3	2
71	The Fires Are Burning. Milbank Quarterly, 2018, 96, 623-626.	2.1	0
72	Common Ground on Health. JAMA - Journal of the American Medical Association, 2018, 320, 2518.	3.8	0

#	Article	IF	CITATIONS
73	Global Budgets in Maryland. JAMA - Journal of the American Medical Association, 2018, 319, 2475.	3.8	25
74	How Do You Solve a Problem Like Juul?. Milbank Quarterly, 2018, 96, 417-420.	2.1	1
75	Crises and Population Health. Milbank Quarterly, 2018, 96, 223-226.	2.1	Ο
76	Emergency Department Utilization Among theÂUninsured During Insurance Expansion inÂMaryland. Annals of Emergency Medicine, 2018, 72, 156-165.	0.3	5
77	The evidence—and acceptability—of taxes on unhealthy foods. Israel Journal of Health Policy Research, 2018, 7, 68.	1.4	8
78	The Opioid Crisis From Research to Practice. Milbank Quarterly, 2017, 95, 24-27.	2.1	6
79	Something new in the air: Paying for community-based environmental approaches to asthma prevention and control. Journal of Allergy and Clinical Immunology, 2017, 140, 1244-1249.	1.5	11
80	Déjà Vu at the FDA. Milbank Quarterly, 2017, 95, 245-248.	2.1	1
81	Relationship Between the American Academy of Pediatrics and Infant Formula Companies. JAMA Pediatrics, 2017, 171, 613.	3.3	9
82	Marketing Claims for Infant Formula Additives and Infant Formula—Reply. JAMA Pediatrics, 2017, 171, 811.	3.3	0
83	Vaccines and the Trump Administration. JAMA - Journal of the American Medical Association, 2017, 317, 1305.	3.8	11
84	Enhancing Transparency at the US Food and Drug Administration. JAMA - Journal of the American Medical Association, 2017, 317, 1621.	3.8	12
85	Marketing Claims for Infant Formula. JAMA Pediatrics, 2017, 171, 105.	3.3	26
86	Public Health Bundles. Milbank Quarterly, 2017, 95, 474-477.	2.1	1
87	Science and the Trump Administration. JAMA - Journal of the American Medical Association, 2017, 318, 1312.	3.8	4
88	Global Budgets for Safety-Net Hospitals. JAMA - Journal of the American Medical Association, 2017, 318, 1759.	3.8	7
89	US Hospital Awards and Community Health Improvement. American Journal of Public Health, 2017, 107, 1076-1077.	1.5	2
90	Power Morcellators, Postmarketing Surveillance, and the US Food and Drug Administration. JAMA - Journal of the American Medical Association, 2017, 318, 325.	3.8	7

#	Article	IF	CITATIONS
91	Hospital Accreditation and Community Health. American Journal of Medicine, 2017, 130, 117-118.	0.6	2
92	Common Ground on Responsibility for Health. Milbank Quarterly, 2017, 95, 718-721.	2.1	0
93	Global Budgets for Rural Hospitals. Milbank Quarterly, 2016, 94, 255-259.	2.1	13
94	Rethinking Science and Politics. Milbank Quarterly, 2016, 94, 39-42.	2.1	2
95	A Stronger Treatment System for Opioid Use Disorders. JAMA - Journal of the American Medical Association, 2016, 315, 2165.	3.8	9
96	Promise and Peril for Generic Drugs. JAMA Internal Medicine, 2016, 176, 733.	2.6	5
97	Population Health Case Reports. JAMA - Journal of the American Medical Association, 2016, 315, 2663.	3.8	13
98	The Adequacy of Individual Hospital Data to Identify High Utilizers and Assess Community Health. JAMA Internal Medicine, 2016, 176, 856.	2.6	12
99	Breaking the gridlock: Regulation of dietary supplements in the United States. Drug Testing and Analysis, 2016, 8, 424-430.	1.6	17
100	Banishing "Stakeholders― Milbank Quarterly, 2016, 94, 476-479.	2.1	12
101	Pharmaceuticals and Public Health. JAMA - Journal of the American Medical Association, 2016, 316, 2083.	3.8	4
102	Violent Injury as a Preventable Condition. Milbank Quarterly, 2016, 94, 708-711.	2.1	1
103	Development of Maryland Local Overdose Fatality Review Teams. Health Promotion Practice, 2016, 17, 596-600.	0.9	7
104	Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion. JAMA - Journal of the American Medical Association, 2016, 315, 984.	3.8	17
105	Role of the FDA in Affordability of Off-Patent Pharmaceuticals. JAMA - Journal of the American Medical Association, 2016, 315, 461.	3.8	22
106	Dear Health Care Lobbyists Milbank Quarterly, 2015, 93, 15-18.	2.1	2
107	An Update on Maryland's All-Payer Approach to Reforming the Delivery of Health Care. JAMA Internal Medicine, 2015, 175, 1083.	2.6	17
108	Electronic Cigarettes: Gateway to Understanding the FDA?. Milbank Quarterly, 2015, 93, 251-254.	2.1	2

#	Article	IF	CITATIONS
109	Public Health and the First Amendment. Milbank Quarterly, 2015, 93, 459-462.	2.1	1
110	Accountability for Health. Milbank Quarterly, 2015, 93, 675-678.	2.1	3
111	On Fear, Distrust, and Ebola. JAMA - Journal of the American Medical Association, 2015, 313, 784.	3.8	13
112	Achieving Health Equity by Design. JAMA - Journal of the American Medical Association, 2015, 313, 1417.	3.8	54
113	Maryland's Global Hospital Budgets — Preliminary Results from an All-Payer Model. New England Journal of Medicine, 2015, 373, 1899-1901.	13.9	53
114	FDA Regulation of Laboratory-Developed Diagnostic Tests. JAMA - Journal of the American Medical Association, 2015, 313, 667.	3.8	31
115	Using Health Care Data to Track and Improve Public Health. JAMA - Journal of the American Medical Association, 2015, 313, 2012.	3.8	8
116	State Leadership in Health Care Transformation. JAMA - Journal of the American Medical Association, 2015, 314, 349.	3.8	6
117	A Spotlight on Sunscreen Regulation. New England Journal of Medicine, 2015, 373, 101-103.	13.9	8
118	The Safety of Prescription Drugs. JAMA - Journal of the American Medical Association, 2015, 314, 233.	3.8	6
119	Unrest in Baltimore. JAMA - Journal of the American Medical Association, 2015, 313, 2425.	3.8	12
120	Neurology and the Affordable Care Act. JAMA Neurology, 2015, 72, 623.	4.5	4
121	Of Mouse and Measles. JAMA - Journal of the American Medical Association, 2015, 313, 1504.	3.8	2
122	The Promotion of Medical Products in the 21st Century. JAMA - Journal of the American Medical Association, 2015, 314, 1795.	3.8	8
123	Working with Communities to Achieve Health Equity in Maryland's Five Health Enterprise Zones. Journal of Health Care for the Poor and Underserved, 2014, 25, 4-10.	0.4	9
124	Health Care and Poverty. JAMA - Journal of the American Medical Association, 2014, 312, 2200.	3.8	1
125	Maryland's All-Payer Approach to Delivery-System Reform. New England Journal of Medicine, 2014, 370, 493-495.	13.9	85
126	On Working for Henry Waxman. Milbank Quarterly, 2014, 92, 186-190.	2.1	0

#	Article	IF	CITATIONS
127	Speaking With Doctors in Restaurants. Milbank Quarterly, 2014, 92, 422-425.	2.1	Ο
128	Chronic Pain, Addiction, and Zohydro. New England Journal of Medicine, 2014, 370, 2061-2063.	13.9	24
129	Confronting the Stigma of Opioid Use Disorder—and Its Treatment. JAMA - Journal of the American Medical Association, 2014, 311, 1393.	3.8	244
130	Treatment for Opioid Use Disorder—Reply. JAMA - Journal of the American Medical Association, 2014, 312, 751.	3.8	1
131	Improving Medical Device Regulation. JAMA Internal Medicine, 2014, 174, 1779.	2.6	3
132	The Strange Journey of Population Health. Milbank Quarterly, 2014, 92, 640-643.	2.1	23
133	Critical Issues in US Health Care. JAMA - Journal of the American Medical Association, 2013, 310, 1945.	3.8	1
134	New Incentive-Based Programs. JAMA - Journal of the American Medical Association, 2013, 310, 259.	3.8	3
135	A Systemic Approach to Containing Health Care Spending. New England Journal of Medicine, 2012, 367, 949-954.	13.9	155
136	Fungal Meningitis From Injection of Contaminated Steroids. JAMA - Journal of the American Medical Association, 2012, 308, 2461.	3.8	17
137	The FDA Safety and Innovation Act. JAMA - Journal of the American Medical Association, 2012, 308, 1437.	3.8	5
138	Toward Innovative Models of Health Care and Financing. JAMA - Journal of the American Medical Association, 2012, 307, 1261.	3.8	9
139	The FDA—A Misunderstood Agency. JAMA - Journal of the American Medical Association, 2011, 306, 1250.	3.8	3
140	Transparency at the Food and Drug Administration. New England Journal of Medicine, 2010, 362, 2341-2343.	13.9	33
141	Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration. New England Journal of Medicine, 2010, 363, 1489-1491.	13.9	136
142	Tobacco Product Regulation — A Public Health Approach. New England Journal of Medicine, 2010, 362, 1753-1756.	13.9	60
143	The FDA as a Public Health Agency. New England Journal of Medicine, 2009, 360, 2493-2495.	13.9	66
144	Over the Counter but No Longer under the Radar — Pediatric Cough and Cold Medications. New England Journal of Medicine, 2007, 357, 2321-2324.	13.9	134

#	Article	IF	CITATIONS
145	Kids First?. International Journal of Health Services, 2000, 30, 763-769.	1.2	1
146	Child health initiatives and journal narrow-mindedness. Lancet, The, 2000, 356, 1626.	6.3	1
147	Phenytoin Dosage. Pediatrics, 1998, 102, 1223-1223.	1.0	3
148	Campaign Contributions from the American Medical Political Action Committee to Members of Congress For or Against the Public Health?. New England Journal of Medicine, 1994, 330, 32-37.	13.9	26
149	The Development and Implementation of a New Hospital Performance Measure to Assess Hospital Contributions to Community Health and Equity. Health Services Research, 0, , .	1.0	2